How PT-141 (Bremelanotide) Works, in Plain English
PT-141, now known by its generic name bremelanotide, is unusual among sexual health medicines: it does not act on blood vessels like sildenafil, but on the brain. It is approved in the United States for a specific condition in women, while in the UK it circulates mostly as an unlicensed ‘research peptide’. Our editorial team explains, without jargon, what it does and where the evidence stands.
Where PT-141 came from
The story begins with a peptide called melanotan II, developed at the University of Arizona in the 1980s and 1990s as a potential sunless tanning agent. It mimics alpha-melanocyte-stimulating hormone (α-MSH), a natural hormone that, among other roles, darkens the skin.
Early volunteers noticed an unexpected effect: spontaneous erections. Wessells and colleagues later studied melanotan II in men with erectile dysfunction and confirmed that the effect originated in the central nervous system rather than in the penis itself.
Palatin Technologies developed a related molecule, bremelanotide, designed to keep the effect on sexual response while reducing some of melanotan II’s broader actions. Bremelanotide is in fact a metabolite of melanotan II, differing by a single chemical group.
After trials of a nasal spray were halted partly because of blood pressure increases, the developers switched to an injectable form. In 2019 the US Food and Drug Administration approved it under the brand name Vyleesi.
The mechanism in simple terms
Our bodies use a family of signalling proteins called melanocortin receptors, numbered MC1 to MC5. MC1 is found mainly in skin pigment cells, while MC3 and MC4 are concentrated in the brain, where they help regulate appetite, energy balance and sexual behaviour.
Bremelanotide is a melanocortin receptor agonist, meaning it switches these receptors on. Its main target for sexual function is believed to be the MC4 receptor in the hypothalamus, an area deep in the brain that coordinates hormonal and behavioural drives.
Animal research, such as work by Pfaus and colleagues in female rats, suggests that activating these receptors increases the release of dopamine in areas linked to motivation and reward. In everyday language, the drug appears to nudge the brain’s ‘wanting’ system rather than the body’s plumbing.
This is a fundamental difference from PDE5 inhibitors like sildenafil, which increase blood flow but do not create desire. It is also why bremelanotide was developed for a disorder of desire rather than of physical arousal alone.
What clinical trials showed
The approval was based on two phase 3 trials known as RECONNECT, published by Kingsberg and colleagues in 2019. They enrolled premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD), a persistent lack of sexual desire that causes personal distress and is not explained by another condition or medicine.
Participants used a 1.75 mg subcutaneous injection as needed before anticipated sexual activity, which is the dose stated in the US labelling. The labelling also limits use to no more than one dose in 24 hours and no more than eight doses per month.
Compared with placebo, women using bremelanotide reported statistically significant improvements in desire scores and a reduction in distress. However, the number of satisfying sexual events did not differ meaningfully, and the absolute improvements were modest.
Evidence in men is limited to earlier, smaller studies, and bremelanotide is not approved for any indication in men. It is not approved for postmenopausal women either.
Side effects and safety concerns
Because bremelanotide acts on brain receptors that influence many functions, side effects are common. In the phase 3 trials nausea was the most frequent, affecting around four in ten users, and it led a notable minority to stop treatment.
| Effect | Why it happens | Comment |
|---|---|---|
| Nausea, vomiting | Central melanocortin activity | Most common, usually after the first doses |
| Facial flushing, headache | Vascular and central effects | Common, usually short-lived |
| Temporary rise in blood pressure, lower heart rate | Melanocortin effects on circulation | Reason it is avoided in uncontrolled hypertension or heart disease |
| Darkening of skin patches (focal hyperpigmentation) | MC1 receptor activation | More likely with frequent use; may not fully reverse |
Bremelanotide can also slow gastric emptying and reduce the absorption of some oral medicines. The US labelling specifically warns about reduced levels of naltrexone taken by mouth.
These issues explain why the drug is prescription-only where it is approved and why it should only be used after medical assessment of the underlying problem.
Legal status and unlicensed ‘research peptides’
Bremelanotide does not have a marketing authorisation in the UK or the European Union. It cannot be legally sold in the UK as a medicine, and products advertised online as ‘PT-141 for research use’ are unlicensed and unregulated.
Unregulated injectable peptides carry several risks that go beyond the drug itself:
- the content and dose may differ from the label or be absent altogether;
- products may not be sterile, risking abscesses and infections;
- sharing injecting equipment risks blood-borne viruses;
- there is no medical oversight of blood pressure or interactions.
The MHRA has repeatedly warned the public against buying medicines, including tanning and sexual enhancement injections, from unregulated online sellers. Products related to melanotan have been linked to skin changes and concerns about moles.
Anyone experiencing low sexual desire should begin with a conversation with a GP or sexual health clinic. Causes such as relationship issues, depression, medicines, hormonal changes and fatigue are common and often treatable.
Editorial conclusions
PT-141, or bremelanotide, is a melanocortin receptor agonist that acts in the brain rather than on blood vessels, influencing desire through pathways involving dopamine.
It is approved in the US only for premenopausal women with HSDD; trials showed modest benefits alongside frequent nausea, flushing, blood pressure changes and skin darkening.
In the UK it is unlicensed, and products sold as research peptides carry additional risks of contamination, wrong dosing and lack of medical supervision.
For more context, read our articles on how ipamorelin works, on the history of mechano growth factor and on the side effects of semaglutide.
References
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899–908.
- Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325–337.
- Dhillon S, Keam SJ. Bremelanotide: first approval. Drugs. 2019;79(14):1599–1606.
- Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201–10204.
- Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96–102.
- Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389–393.
